SLC5A2 and type 2 diabetes mellitus: ,8,77,78 In a meta-analysis of 13 SGLT2 inhibitor trials, the risk of lower limb amputation was low among patients allocated to an SGLT2 inhibitor, accounting for 1 lower limb amputation event per 1,000 patient-years in patients with T2DM.29